Ottawa extends $500M-a-year rare-disease drug funding and bridges $1.2B for mental health care

The federal government used Friday's meeting of Canada's health ministers in Winnipeg to lock in funding patients had been waiting on — and to buy time on the bigger fight.

Federal Health Minister Marjorie Michel told her provincial and territorial counterparts that the $500 million a year for the National Strategy for Drugs for Rare Diseases, which was set to expire next year, will now be funded on an ongoing basis, The Canadian Press reported. For patients waiting on expensive drugs for rare conditions, the decision removes a funding cliff that had been looming.

Michel also confirmed a move she announced late Wednesday: a one-year extension of the $1.2 billion in annual funding for mental health, addictions and home care that had been set to expire next March. The extension bridges the provinces to the new fall federal budget schedule, she said Friday.

But the deeper question — how much Ottawa transfers to the provinces for health care in the long run — stays unresolved. Ministers agreed that public servants will "start the work on what will be the next step for the next negotiation on Canada Health Transfers and other agreements," Michel said, with another ministers' meeting set before the end of the year.

Manitoba Health Minister Uzoma Asagwara, who co-chaired Friday's meeting, said there was much left to negotiate, but added it was good that the federal minister is listening. "We will absolutely keep the pressure on," Asagwara said.

For Canadians, the takeaway is split. If you or someone you love depends on a rare-disease drug, Friday brought real certainty. But if you're waiting for shorter ER lines or a family doctor, the main event — the Canada Health Transfer negotiation that decides the long-term money — is still on the runway, with the fall budget now the next marker.